Amylyx says Phase 3 LUCIDITY trial of avexitide cuts post-bariatric hypoglycemia events 55% vs placebo
AMLX•Phase 3 LUCIDITY results
Amylyx reported positive topline Phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia following Roux-en-Y surgery.
The trial showed fewer serious hypoglycemic events versus placebo, supporting a potential first approved therapy for the condition.
Regulatory timeline and next steps
Management plans to file a New Drug Application with the FDA by end of 2026, targeting a 2027 launch if cleared.
Data will be presented at a future medical meeting; an open-label extension remains ongoing.
